Drug safety and tolerability in prophylactic migraine treatment

L. Vécsei, Zsófia Majláth, Délia Szok, Anett Csáti, J. Tajti

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction: Migraine is a frequent, disabling primary headache disorder, whose pathomechanism is not yet fully understood. Prophylactic treatment is advisable for migraineurs with severe or highly frequent attacks, which impair the quality of life.Areas covered: The different types of prophylactic migraine drugs are discussed, with particular regard to potential adverse effects and safety issues. β-Adrenergic blockers, antiepileptic drugs and calcium-channel blockers are drugs widely used for migraine prevention, whereas complementary medicine and onabotulinumtoxin A can be used in selected cases.Expert opinion: The background of the recurrence and chronification of migraine attacks has not been fully clarified, and causative preventive therapy is therefore not currently available. The tolerability and adverse effects of the currently used medications often limit their use. β-Adrenergic receptor blockers may induce adverse cardiovascular events, whereas flunarizine is frequently associated with a weight gain and depression. As most migraine sufferers are young women of child-bearing age, the use of valproate is limited. Topiramate is associated with central nervous system-related side effects. There is a need for future development of pathomechanism-based preventive drugs, and personalized therapy tailored to the patient.

Original languageEnglish
Pages (from-to)667-681
Number of pages15
JournalExpert Opinion on Drug Safety
Volume14
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Migraine Disorders
Safety
Adrenergic Antagonists
Pharmaceutical Preparations
Primary Headache Disorders
Flunarizine
Therapeutics
Calcium Channel Blockers
Expert Testimony
Valproic Acid
Complementary Therapies
Anticonvulsants
Adrenergic Receptors
Weight Gain
Central Nervous System
Quality of Life
Recurrence
Drug Therapy

Keywords

  • Efficacy
  • Migraine
  • Prophylactic treatment
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Drug safety and tolerability in prophylactic migraine treatment. / Vécsei, L.; Majláth, Zsófia; Szok, Délia; Csáti, Anett; Tajti, J.

In: Expert Opinion on Drug Safety, Vol. 14, No. 5, 01.05.2015, p. 667-681.

Research output: Contribution to journalArticle

Vécsei, L. ; Majláth, Zsófia ; Szok, Délia ; Csáti, Anett ; Tajti, J. / Drug safety and tolerability in prophylactic migraine treatment. In: Expert Opinion on Drug Safety. 2015 ; Vol. 14, No. 5. pp. 667-681.
@article{f9a613e69514458385b24e20159e16d5,
title = "Drug safety and tolerability in prophylactic migraine treatment",
abstract = "Introduction: Migraine is a frequent, disabling primary headache disorder, whose pathomechanism is not yet fully understood. Prophylactic treatment is advisable for migraineurs with severe or highly frequent attacks, which impair the quality of life.Areas covered: The different types of prophylactic migraine drugs are discussed, with particular regard to potential adverse effects and safety issues. β-Adrenergic blockers, antiepileptic drugs and calcium-channel blockers are drugs widely used for migraine prevention, whereas complementary medicine and onabotulinumtoxin A can be used in selected cases.Expert opinion: The background of the recurrence and chronification of migraine attacks has not been fully clarified, and causative preventive therapy is therefore not currently available. The tolerability and adverse effects of the currently used medications often limit their use. β-Adrenergic receptor blockers may induce adverse cardiovascular events, whereas flunarizine is frequently associated with a weight gain and depression. As most migraine sufferers are young women of child-bearing age, the use of valproate is limited. Topiramate is associated with central nervous system-related side effects. There is a need for future development of pathomechanism-based preventive drugs, and personalized therapy tailored to the patient.",
keywords = "Efficacy, Migraine, Prophylactic treatment, Safety, Tolerability",
author = "L. V{\'e}csei and Zs{\'o}fia Majl{\'a}th and D{\'e}lia Szok and Anett Cs{\'a}ti and J. Tajti",
year = "2015",
month = "5",
day = "1",
doi = "10.1517/14740338.2015.1014797",
language = "English",
volume = "14",
pages = "667--681",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Drug safety and tolerability in prophylactic migraine treatment

AU - Vécsei, L.

AU - Majláth, Zsófia

AU - Szok, Délia

AU - Csáti, Anett

AU - Tajti, J.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: Migraine is a frequent, disabling primary headache disorder, whose pathomechanism is not yet fully understood. Prophylactic treatment is advisable for migraineurs with severe or highly frequent attacks, which impair the quality of life.Areas covered: The different types of prophylactic migraine drugs are discussed, with particular regard to potential adverse effects and safety issues. β-Adrenergic blockers, antiepileptic drugs and calcium-channel blockers are drugs widely used for migraine prevention, whereas complementary medicine and onabotulinumtoxin A can be used in selected cases.Expert opinion: The background of the recurrence and chronification of migraine attacks has not been fully clarified, and causative preventive therapy is therefore not currently available. The tolerability and adverse effects of the currently used medications often limit their use. β-Adrenergic receptor blockers may induce adverse cardiovascular events, whereas flunarizine is frequently associated with a weight gain and depression. As most migraine sufferers are young women of child-bearing age, the use of valproate is limited. Topiramate is associated with central nervous system-related side effects. There is a need for future development of pathomechanism-based preventive drugs, and personalized therapy tailored to the patient.

AB - Introduction: Migraine is a frequent, disabling primary headache disorder, whose pathomechanism is not yet fully understood. Prophylactic treatment is advisable for migraineurs with severe or highly frequent attacks, which impair the quality of life.Areas covered: The different types of prophylactic migraine drugs are discussed, with particular regard to potential adverse effects and safety issues. β-Adrenergic blockers, antiepileptic drugs and calcium-channel blockers are drugs widely used for migraine prevention, whereas complementary medicine and onabotulinumtoxin A can be used in selected cases.Expert opinion: The background of the recurrence and chronification of migraine attacks has not been fully clarified, and causative preventive therapy is therefore not currently available. The tolerability and adverse effects of the currently used medications often limit their use. β-Adrenergic receptor blockers may induce adverse cardiovascular events, whereas flunarizine is frequently associated with a weight gain and depression. As most migraine sufferers are young women of child-bearing age, the use of valproate is limited. Topiramate is associated with central nervous system-related side effects. There is a need for future development of pathomechanism-based preventive drugs, and personalized therapy tailored to the patient.

KW - Efficacy

KW - Migraine

KW - Prophylactic treatment

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84928311696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928311696&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1014797

DO - 10.1517/14740338.2015.1014797

M3 - Article

C2 - 25676133

AN - SCOPUS:84928311696

VL - 14

SP - 667

EP - 681

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 5

ER -